Sollievo Pharmaceuticals

Sollievo Pharmaceuticals

Early Stage

When Minutes Matter

When Minutes Matter

Overview

Raised this Round: Raised: $40,715

Total Commitments ($USD)

Platform

StartEngine

Start Date

08/04/2022

Close Date

12/16/2022

Min. Goal
$10,000
Max. Goal
$1,070,000
Min. Investment

$400

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.00

Pre-Money Valuation

$20,000,000

Year Founded

2018

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

San Juan Capistrano, California

Business Type

Growth

Sollievo Pharmaceuticals, with a valuation of $20 million, is raising funds on StartEngine. The company has developed a fast-acting sedative in the form of an injectable benzodiazepine. The sedative, Proviza, causes rapid sedation in agitated and aggressive patients and protects healthcare staff from injuries and abuse. Proviza is highly water-soluble and brings about sedation in 5-10 minutes. Robert Schultz founded Sollievo Pharmaceuticals in February 2018. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,070,000. The campaign proceeds will be used for the completion of the patient clinical trial, submission of the New Drug Application, and receiving FDA approval.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-189,478

$-1,164,009

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$153

$1,157

Accounts Receivable

$0

$0

Total Assets

$153

$1,157

Short-Term Debt

$772,225

$655,821

Long-Term Debt

$1,252,890

$1,180,819

Total Liabilities

$2,025,115

$1,836,640

Financials as of: 08/04/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Sollievo Pharmaceuticals on StartEngine 2022
Platform: StartEngine
Security Type: Equity - Common
Valuation: $20,000,000
Price per Share: $2.00

Follow company

Follow Sollievo Pharmaceuticals on StartEngine 2022

Buy Sollievo Pharmaceuticals's Deal Report

Warning: according to the close date for this deal, Sollievo Pharmaceuticals may no longer be accepting investments.

Sollievo Pharmaceuticals Deal Report

Get KingsCrowd’s comprehensive report on Sollievo Pharmaceuticals including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Sollievo Pharmaceuticals is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Sollievo Pharmaceuticals deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge